Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 501
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Matthew Craig Kapusta | CEO & Exec. Director | 1.16M | N/A | 1972 |
Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 566.36k | N/A | 1973 |
Mr. Pierre Caloz | Chief Operating Officer | 951.1k | N/A | 1972 |
Dr. Ricardo Dolmetsch Ph.D. | Pres of R&D | 911.07k | N/A | 1969 |
Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | N/A | N/A | N/A |
Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer | N/A | N/A | 1962 |
Dr. Tamara Tugal Ph.D., MBA | Bus. Devel. Director | N/A | N/A | N/A |
Ms. Erin Boyer | Chief People & Culture Office | N/A | N/A | N/A |
Ms. Maria E. Cantor | Chief Corp. Affairs Officer | N/A | N/A | 1968 |
Mr. Richard Porter Ph.D. | Chief Bus. Officer | N/A | N/A | N/A |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS governance QualityScore as of 1 June 2023 is 3. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 3.